0001209191-18-046706.txt : 20180815
0001209191-18-046706.hdr.sgml : 20180815
20180815074611
ACCESSION NUMBER: 0001209191-18-046706
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180813
FILED AS OF DATE: 20180815
DATE AS OF CHANGE: 20180815
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Goldman Steven M.
CENTRAL INDEX KEY: 0001568216
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38135
FILM NUMBER: 181019745
MAIL ADDRESS:
STREET 1: C/O DOVA PHARMACEUTICALS, INC.
STREET 2: 240 LEIGH FARM ROAD, SUITE 245
CITY: DURHAM
STATE: NC
ZIP: 27707
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dova Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001685071
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813858961
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2530 MERIDIAN PARKWAY
STREET 2: SUITE 300
CITY: DURHAM
STATE: NC
ZIP: 27713
BUSINESS PHONE: 919-806-4487
MAIL ADDRESS:
STREET 1: 2530 MERIDIAN PARKWAY
STREET 2: SUITE 300
CITY: DURHAM
STATE: NC
ZIP: 27713
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-08-13
0
0001685071
Dova Pharmaceuticals, Inc.
DOVA
0001568216
Goldman Steven M.
C/O DOVA PHARMACEUTICALS, INC.
240 LEIGH FARM ROAD, SUITE 245
DURHAM
NC
27707
1
0
0
0
Common Stock
2018-08-13
4
M
0
1832
7.32
A
125001
D
Common Stock
5000
I
By LLC
Stock Option (Right to Buy)
7.32
2018-08-13
4
M
0
1832
0.00
D
2027-05-24
Common Stock
1832
20168
D
These shares are held by the Steven M. Goldman Family LLC (the "LLC"), of which the Reporting Person is the Managing Member. The voting and investment decisions of the LLC are made by an independent external asset manager. The Reporting Person disclaims beneficial ownership of the shares held by the LLC except to the extent of his pecuniary interest in the LLC, if any, and the inclusion of these shares on this report shall not be deemed an admission that the Reporting Person beneficially owns the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or any other purpose.
The option vests over a period of three years as follows: (i) one-third of the total shares subject to the option shall vested on May 25, 2018, and (ii) 1/36th of total shares subject to the option shall vest monthly thereafter over the remaining two years of the vesting period, subject to the Reporting Person's continuous service with the Issuer on each such date. The option allows for early exercise, subject to the Issuer's repurchase option, with respect to any unvested shares of Common Stock.
/s/ Darren DeStefano, Attorney-in-Fact
2018-08-15